 Thrombocytopenia
"Thrombocytopenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subnormal level of BLOOD PLATELETS.
| Descriptor ID |
D013921
|
| MeSH Number(s) |
C15.378.140.855
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thrombocytopenia".
Below are MeSH descriptors whose meaning is more specific than "Thrombocytopenia".
This graph shows the total number of publications written about "Thrombocytopenia" by people in this website by year, and whether "Thrombocytopenia" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 0 | 3 | 3 | | 1997 | 2 | 0 | 2 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 2 | 2 | 4 | | 2001 | 2 | 4 | 6 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 3 | 0 | 3 | | 2006 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 2 | 1 | 3 | | 2012 | 2 | 3 | 5 | | 2013 | 0 | 5 | 5 | | 2014 | 4 | 2 | 6 | | 2015 | 5 | 4 | 9 | | 2016 | 5 | 2 | 7 | | 2017 | 2 | 2 | 4 | | 2018 | 2 | 1 | 3 | | 2019 | 4 | 1 | 5 | | 2020 | 4 | 1 | 5 | | 2021 | 9 | 1 | 10 | | 2022 | 10 | 0 | 10 | | 2023 | 6 | 0 | 6 | | 2024 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Thrombocytopenia" by people in Profiles.
-
Pirabe A, Schrottmaier WC, Mehic D, Hackl H, Fr?hwirth S, Schmuckenschlager A, Beck S, Gebhart J, Gleixner K, Sperr W, Assinger A. Impaired hemostatic and immune functions of platelets after acute thrombocytopenia. J Thromb Haemost. 2025 Mar; 23(3):1052-1065.
-
Giles JB, Martinez KL, Steiner HE, Klein A, Ooi A, Pryor J, Sweitzer N, Fuchs D, Karnes JH. Association of Metal Cations with the Anti-PF4/Heparin Antibody Response in Heparin-Induced Thrombocytopenia. Cardiovasc Toxicol. 2024 Sep; 24(9):968-981.
-
Wheeler AP, Snyder EL, Refaai M, Cohn CS, Poisson J, Fontaine M, Sehl M, Nooka AK, Uhl L, Spinella PC, Fenelus M, Liles D, Coyle T, Becker J, Jeng M, Gehrie EA, Spencer BR, Young P, Johnson A, O'Brien JJ, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla ST, Liu K, Bentow S, Varrone J, Benjamin RJ, Corash LM. Acute pulmonary injury in hematology patients supported with pathogen-reduced and conventional platelet components. Blood Adv. 2024 05 14; 8(9):2290-2299.
-
D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 04 13; 403(10435):1460-1471.
-
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study. Blood Adv. 2023 10 24; 7(20):6339-6350.
-
Harding E, Cho S, Garrington T, Mandell E. A Neonate Presenting with Cholestasis and Thrombocytopenia. Neoreviews. 2023 09 01; 24(9):e583-e586.
-
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers. Int J Gynecol Cancer. 2023 08 07; 33(8):1208-1214.
-
Giles JB, Rollin J, Martinez KL, Selleng K, Thiele T, Pouplard C, Sheppard JI, Heddle NM, Phillips EJ, Roden DM, Gruel Y, Warkentin TE, Greinacher A, Karnes JH. Laboratory and demographic predictors of functional assay positive status in suspected heparin-induced thrombocytopenia: A multicenter retrospective cohort study. Thromb Res. 2023 09; 229:198-208.
-
Jess J, Yates B, Dulau-Florea A, Parker K, Inglefield J, Lichtenstein D, Schischlik F, Ongkeko M, Wang Y, Shahani S, Cullinane A, Smith H, Kane E, Little L, Chen D, Fry TJ, Shalabi H, Wang HW, Satpathy A, Lozier J, Shah NN. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. J Immunother Cancer. 2023 06; 11(6).
-
Dawson MA, Borthakur G, Huntly BJP, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA, Davies FE, Morgan GJ, Glass JL, Kamdar M, Mateos MV, Tovar N, Yeh P, Delgado RG, Basheer F, Marando L, Gallipoli P, Wyce A, Krishnatry AS, Barbash O, Bakirtzi E, Ferron-Brady G, Karpinich NO, McCabe MT, Foley SW, Horner T, Dhar A, Kremer BE, Dickinson M. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2023 02 16; 29(4):711-722.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|